AeroVironment's backlog explosion suggests drone warfare is now a structural budget priority, not a trend

AeroVironment posted a blowout quarter with revenue more than doubling and its funded backlog climbing 65% to $1.2 billion, triggering a rally across the broader drone sector.

The backlog figure is the real signal here: governments are locking in orders well ahead of delivery, which means this is not a one-quarter spike but a multi-year demand story that competitors will scramble to chase.

Nike's beat is a tariff-refund illusion, not a genuine recovery

Nike topped Wall Street's estimates for both profit and revenue, but the headline numbers were flattered by a one-time tariff refund rather than genuine improvement in how the business is actually selling shoes and apparel.

With China sales down 12% and North America under pressure, the underlying demand picture remains weak, which means the market should treat this beat as a bookkeeping win rather than evidence that Nike's turnaround has arrived.

The FDA's Zyn ruling hands Philip Morris a legal weapon its cigarette rivals cannot copy

The FDA approved 20 of Philip Morris's Zyn nicotine pouch products to carry modified-risk labels, meaning the company can now legally market Zyn as a lower-risk alternative to cigarettes, a claim no traditional tobacco product is allowed to make.

This is not just a regulatory checkbox: it gives Zyn a marketing advantage in the fastest-growing corner of the nicotine market at exactly the moment traditional cigarette volumes are in structural decline, widening the gap between Philip Morris and rivals still dependent on combustible products.